Financial Releases

New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan CHASKA, Minn. , May 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company” Nasdaq: LFCR), a fully integrated contract development and

CHASKA, Minn. , May 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a conference call to discuss fiscal 2023 third quarter financial results.

CHASKA, Minn. , April 14, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received a notice (“Notice”) on April 13, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in

CHASKA, Minn. , April 06, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has completed the sale of all of its Curation Foods’ assets related to the O Olive Oil

Provides $10 million upfront cash commitment to Lifecore for infrastructure preparation and production capacity preparation Customer to provide reimbursement for up to $15 million in capital expenditures to expand capacity Contemplates negotiation of multi-year amendment to extend and expand

CHASKA, Minn. , March 16, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the Board of Directors of the Company (the “Board”) intends to initiate a process to

Company Announces Intention to Explore Strategic Alternatives Signs Term Sheet with Key Customer to Materially Expand Commercial Relationship Expands Development Pipeline from 24 to 25 Active Projects as of Fiscal Second Quarter-end Subsequently Transitioned Three Projects to Commercialization with

Proceeds to be used for debt paydown CHASKA, Minn. , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has completed the sale of its Curation Food’s

CHASKA, Minn. , Jan. 11, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), announced today that it received a notice (“Notice”) on January 11, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in

$38.75 million Private Placement of Series A Convertible Preferred Stock to Support Working Capital and Capital Expenditures While Pursuing Ongoing Divestment Process of non-CDMO Assets Credit Facilities Amended to Increase Liquidity and Provide Financial Covenant Relief Nathaniel Calloway, PhD and